The aim is find two potent and complimentary antibodies that can be combined into a $25 therapy for Covid-19 patients who haven’t been vaccinated, couldn’t be vaccinated, or have developed a breakthrough infection. “We now have a framework for selecting durable antibody cocktails for Covid-19 treatment,” said Ollmann Saphire, who is president and chief executive officer at the La Jolla Institute. The map, produced in collaboration with 56 research groups on four continents, is enabling scientists to devise blueprints for better vaccines and treatments to thwart the hyper-infectious delta strain, which has become dominant globally, and its successors.
